Evoke taps new president for North America, continues talent expansion

Advertising Word Image
Evoke, part of Huntsworth Health, continues to build up staff, and its latest hire is a new president of North America. (Alpha Stock Images)

Evoke is continuing to grow its talent with the hire of Jennifer O’Dwyer as its new president of North America. She takes over for Tom Donnelly, who moved to the newly created position of chief growth officer across all Evoke Group brands.

O’Dwyer was associate partner and director of client services at CDM New York for almost 13 years, and while most of her experience has been in healthcare provider marketing, she has worked in consumer health as well.

“It was a big decision to leave (CDM), but I was at the point where I needed new problems, new opportunities and a different feel in an agency,” she said.

At Evoke, she said she plans to focus on building client partnerships and retaining and recruiting talent in the wake of the agency’s growth.

RELATED: Cannes Lions Health puts members from Evoke, FCB on pharma ad judging panel

“We are actively looking at different service models that I think are very much in line with the nimble mindset of Evoke and will help us cut through some of the complexities that our clients are up against,” she said.

Last year, Evoke simplified its agency brand portfolio—then called Evoke Health, Firsthand, Fabric, Traverse HealthStrategy, Nitrogen Health, Tonic Life Communications and AboveNation Media—under the single integrated Evoke agency brand. The idea was to work through its six core practices—professional marketing, consumer and patient marketing, market access, PR and influence, media and consulting—instead of through individual agencies.

In May, Evoke merged its public relations and influence practice with Kyne, doubling its size to become Evoke Kyne. It's now one of the largest health communications agencies in the world.

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.